EMEA-002255-PIP01-17
Key facts
Active substance |
polatuzumab vedotin
|
Therapeutic area |
Oncology
|
Decision number |
P/0117/2018
|
PIP number |
EMEA-002255-PIP01-17
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Roche Registration Limited
Tel. +41 616879411
E-mail: global.paediatrics@roche.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|